Guideline Recommendations for Ifosfamide and Mesna Administration in Soft Tissue Sarcoma

Mesna Dosing Strategies for Standard‑Dose Ifosfamide

Mandatory urothelial protection: Mesna must be given with every ifosfamide course to prevent hemorrhagic cystitis. For standard‑dose regimens (≤ 2.5 g/m²/day) the total daily mesna dose should equal 60 % of the ifosfamide dose when administered as three intravenous (IV) boluses, or 100 % of the ifosfamide dose when using a combined IV/oral schedule for doses ≤ 2.0 g/m²/day. 1
All‑IV three‑bolus schedule (preferred for doses > 2.0 g/m²/day):
Combined IV/oral schedule (acceptable for doses ≤ 2.0 g/m²/day):
Safety measure for oral mesna: If a patient vomits within 2 hours after an oral mesna dose, repeat that oral dose or switch to an IV mesna administration to maintain protection. 1

Pre‑infusion bolus: Deliver 20 % of the total planned ifosfamide dose as an IV mesna bolus immediately before starting the continuous infusion.
Continuous mesna infusion: Follow the bolus with a continuous mesna infusion at 40 % of the ifosfamide dose, continuing for 12–24 hours after the ifosfamide infusion ends. This schedule compensates for the prolonged drug exposure inherent to continuous infusion regimens. 1

Uncertain optimal mesna dosing: The ideal mesna dose and schedule for very high‑dose ifosfamide (> 2.5 g/m²/day) have not been established.
Increased exposure requires more intensive mesna: High‑dose ifosfamide has a longer half‑life, necessitating more frequent and prolonged mesna administration to achieve maximal uroprotection. Current practice favors the all‑IV mesna regimen for these high‑dose protocols. 1

AI (doxorubicin + ifosfamide) efficacy: The combination of doxorubicin and ifosfamide yields the highest response rates among chemotherapy options for unresectable or metastatic soft‑tissue sarcoma, although it does not improve overall survival compared with doxorubicin alone. 4
Preferred use of adequate‑dose AI: Multi‑agent chemotherapy with an adequate‑dose AI regimen is recommended when tumor shrinkage is clinically advantageous and the patient has good performance status. 5

Hemorrhagic cystitis surveillance: No specific evidence‑based monitoring protocol exists beyond routine clinical surveillance of urine for hematuria during ifosfamide therapy. Adequate hydration and maintenance of urine output remain essential supportive measures. 1